SEC Comment Letter for Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) (MBRX) — Oct 23, 2018
Moleculin Biotech, Inc. (MBRX) (CIK 0001659617)
Date: Oct. 23, 2018 · CIK: 0001659617 · Accession: 0000000000-18-033221
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227845
Letter
October 23, 2018 Walter Klemp Chief Executive Officer Moleculin Biotech, Inc. 5300 Memorial Drive, Suite 950 Houston, TX 77007 Re:Moleculin Biotech, Inc. Registration Statement on Form S-1 Filed October 15, 2018 File No. 333-227845 Dear Mr. Klemp: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Cavas S. Pavri
Show Raw Text
October 23, 2018
Walter Klemp
Chief Executive Officer
Moleculin Biotech, Inc.
5300 Memorial Drive, Suite 950
Houston, TX 77007
Re:Moleculin Biotech, Inc.
Registration Statement on Form S-1
Filed October 15, 2018
File No. 333-227845
Dear Mr. Klemp:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Cavas S. Pavri